Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

AstraZeneca

Clovis Oncology

Denali Therapeutics

Eli Lilly

Morphosys AG - ADR

Pfizer

Clovis Oncology Inc. ( CLVS , Financial) and Denali Therapeutics Inc. ( DNLI , Financial) are among the most likely biotechs to be acquired, according to industry publications. Denali, by far, would be the most expensive of the pair with a market cap of $6.4 billion, while Clovis is far more digestible with a market value of only $567 million.

Biotech Takeovers Moved at Snail's Pace in 2nd Quarter

Biogen Inc (NASDAQ: BIIB) is providing its controversial and expensive new Alzheimer's drug, free of charge for some patients amid slow claim reviews by Medicare, reports Reuters, citing sources familiar with the situation. 'Aduhelm' given as a monthly infusion was approved by the FDA in June even though one of Biogen's two large trials failed to show a benefit for patients diagnosed with the incurable mind-wasting disease.

Amid Medicare Uncertainty, Biogen Offers Its Alzheimer's Drug For Free

Aduhelm costs $56,000 a year and some insurers have been slow to make reimbursements, Reuters reported. Doctors also are questioning the drug's effectiveness.

Biogen Is Giving Away Its Controversial Alzheimer's Drug: Report

It's bound to happen eventually, so it's best to have a contingency plan.

Biogen: What to Do When Your Investment Thesis Is Disproven

A recent regulatory approval could make this company worth serious consideration.

Warren Buffett Sold Off This Biotech Stock. Should You?

Axsome Therapeutics

Here are three reasons why a buyout just might happen.

Could Biogen Acquire Axsome Therapeutics?

AbbVie

Bristol-Myers

General Motors

Kroger

Merck

Buffett stocks are a hot topic among investors as they look to go long on some fresh plays. Kroger and Aon are among Berkshire's favorites.

7 Buffett Stocks to Buy (and Sell) if You Want to Be Like Berkshire

Yesterday, Warren Buffett (Trades, Portfolio)'s Berkshire Hathaway ( BRK.A , Financial)( BRK.B , Financial) published its 13F report for the period ending June 30.

Warren Buffett Sells Biotech Holdings After a Year

Buffett's company established stakes in Merck, AbbVie, and Bristol Myers Squibb in the second half of last year, yet it slashed all three positions.

Warren Buffett's Berkshire Hathaway sold Biogen, halved its Merck stake, and boosted its Kroger bet. Here's a closer look at its key trades in Q2.

Warren Buffett-led Berkshire Hathaway Inc (NYSE: BRK-A) (NYSE: BRK-B) sharply lowered its exposure in General Motors Co (NYSE: GM), Merck & Co Inc (NYSE: MRK), AbbVie Inc (NYSE: ABBV), Bristol-Myers Squibb Co (NYSE: BMY) and added positions in Kroger Inc (NYSE: KR) and Aon Plc (NYSE: AON), in the second quarter, regulatory filings revealed on Monday. What Happened: The Omaha, Nebraska-based conglomerate disclosed it has trimmed its position in the legacy automaker GM by 10.44%, as it shed 60 million shares, lowering its total stake in GM to $3.55 billion at the end of June, compared with $3.85 billion a quarter ago.

Apple, GM, Kroger, AbbVie, Merck, Bristol Myers Squibb, Biogen — How Warren Buffett's Berkshire Adjusted Its Portfolio In Q2

Axalta Coating Systems

Chevron

Liberty Global Ltd

Marsh & McLennan

Organon & Co

U.S. Bancorp

Berkshire Hathaway CEO Warren Buffett and his team were bears yet again in Q2 2021, hacking away at a large number of positions while only adding to a handful.

11 Stocks Warren Buffett Is Selling (And 3 He's Buying)

Warren Buffett's Berkshire Hathaway Inc said on Monday it trimmed or eliminated its stakes in several pharmaceutical companies, and reported a small new stake in a Merck & Co spinoff, Organon & Co.

Buffett's Berkshire pares drug holdings, sheds Axalta, Biogen

The famed investor's company also sold some Chevron and General Motors shares, and boosted its stakes in Aon, Kroger, and RH.

Warren Buffett's Berkshire Hathaway sold its Biogen stake last quarter - and slashed its pharmaceutical bets

It might be that Biogen, too, is abandoning the theory that amyloid plaque is the cause of the disease.

Why Is Biogen Pursuing a New Direction in Alzheimer's Research?

Cassava Sciences Inc

The answer is more complicated than you think.

How Much Should An Alzheimer's Drug Cost?

Who will emerge victorious in the race to help Alzheimer's patients?

Cassava Sciences vs. Biogen

Amgen

VanEck Vectors Biotech ETF

Gilead Sciences

iShares Nasdaq Biotechnology ETF

SPDR S&P Biotech ETF

Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.

How Are Biotech ETFs Reacting to These Q2 Earnings Releases?

Biogen has been in the news recently with their new Alzheimer's therapy coming under scrutiny for its quick approval by the FDA.

Biogen: Beyond The New Alzheimer's Drug

The Department of Veterans Affairs (VA) has decided not to include the new Alzheimer's drug developed by Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC: ESALY), Stat News reported citing a notice issued by the federal agency. The department has cited the lack of evidence of "a robust and meaningful clinical benefit" alongside safety concerns.

Biogen's New Alzheimer's Drug Turned Away By Veterans Affairs

Why I Sold My Biogen Stock

Annovis Bio

Anavex Life Sciences

Biogen's Aduhelm performed no better than placebo in non-ApoE4 carriers and only slightly slowed down the progression of Alzheimer's disease in ApoE4 carriers.

Detours In The Golden Age Of Alzheimer's Drug Stock Investments

Biopharmaceutical company Biogen ( BIIB , Financial) added 61 basis points to the Fund's return, as its stock surged from $279.75 to $346.27, for a total return of 23.8%. Biogen develops drugs that treat neurological and neurogenerative disease, including multiple sclerosis and spinal muscular atrophy.

Parnassus Comments on Biogen

CAMBRIDGE, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced results from the two-year prospective, randomized, interventional, controlled, open-label Phase 3b NOVA study (NCT03689972). NOVA was designed to estimate a potential difference between the efficacy of every six-week (Q6W) 300mg natalizumab intravenous (IV) administration compared to the efficacy of the approved every four-week (Q4W) dose in people treated with TYSABRI® (natalizumab) (n=499) for relapsing-remitting multiple sclerosis (MS) after at least one year of disease stability on a Q4W IV dosing schedule.

Biogen Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting Multiple Sclerosis

Probably. The FDA approval for Biogen's Alzheimer's disease drug, Aduhelm, remains highly controversial.

Will Biogen Be Able to Move Past the Drama Surrounding Its Alzheimer's Disease Drug?

Aduhelm was approved by the FDA, priced at $56,000/year, but it isn't a cure for Alzheimer's. The post Biogen: Does Aduhelm Make it the Next Dendreon?

News for Biogen Stock (BIIB)